Drug intelligence / Profile preview

GS1-144

Development stage: Phase 2
Lead developer: Changchun GeneScience Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

GS1-144 is an orally administered small molecule drug under development for the treatment of vasomotor symptoms, particularly in postmenopausal women. It acts as an antagonist of the neurokinin 3 receptor (NK-3R), a target implicated in the regulation of thermoregulation and vasomotor function. The drug is being developed by Changchun GeneScience Pharmaceutical (also referred to as Changchun Jinsai Pharmaceutical), a subsidiary of Changchun High-Tech Industry Group, with clinical trials currently ongoing in China and the USA. As of early 2025, GS1-144 has reached Phase II clinical trials for moderate to severe vasomotor symptoms in postmenopausal women[1][4][7].

Other names: GS1 144GS-1 144GS 1 144

Targets

TACR3 (Neurokinin 3 Receptor)

Beyond the preview

Go deeper on GS1-144.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GS1-144.

Explore the full profile